Grunenthal gains rights to AcelRx's Zalviso in potential $250M deal

German firm Grunenthal secured the rights to commercialize AcelRx Pharmaceuticals' drug-device pain combination product Zalviso in certain countries in Europe and Australia. AcelRx will keep the rights to the product, which is under regulatory review in both the U.S. and Europe, in other territories including U.S. and Asia. The deal entitles AcelRx to $30 million up-front and about $220 million in potential milestone fees plus sales royalties.

View Full Article in:

BioWorld (free content) · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA